Jun 08, 2022 / 02:20PM GMT
Malgorzata Maria Kaczor Andrew - William Blair & Company L.L.C., Research Division - Partner
Good morning, everyone. Welcome again to day 3 of the William Blair Growth Stock Conference. Really appreciate everyone being here.
For those of you that don't know me, my name is Margaret Kaczor. I am the research analyst here at William Blair & Company who covers ResMed. I am required to inform you that you can obtain a complete list of research disclosures or potential conflicts of interest at williamblair.com.
Now we're very pleased to have Rob Douglas, President and COO and Interim Head now of Sleep and Respiratory Care Business; as well as Dave Pendarvis, Chief Administrative Officer and Global General Counsel, with us today.
Again, I offer a couple of sentences maybe before throwing it over to Rob, but it's been a very eventful few years for the sleep apnea market. Frankly, beginning with what seemed like an acceleration going into COVID, then COVID happened and then there's a huge demand for ventilatory support products. And then one of your competitors left the market
Resmed Inc at William Blair Growth Stock Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers